| Phase | Sponsor | Indication | Status (as of Apr 2026) | |-------|---------|------------|------------------------| | | Oksen Therapeutics | Type‑2 Diabetes with MCI (T2DM‑MCI) | IND filing planned Q4 2026 | | Phase I | Oksen Therapeutics (planned) | Safety, PK, and PD in healthy volunteers | Dose‑escalation (single ascending dose 5–150 mg) | | Phase Ib/IIa | Oksen Therapeutics (planned) | Proof‑of‑concept in T2DM‑MCI patients (n ≈ 60) | Primary endpoints: change in HbA1c, ADAS‑Cog13 at 12 weeks | | Phase IIb (partner‑led) | NeuroMetrix Inc. | Early AD (prodromal) | Candidate for combination with anti‑amyloid antibody |
The synthetic route to OKSN‑191 is patented (WO 2023/018721) and is described in broad strokes in public filings: oksn-191
Its enduring legacy is proven by the simple fact that people are still typing that six-character string into search engines years after its release. It is a code that has become a shorthand for quality, depth, and a specific brand of Japanese cinematic sorrow. | Phase | Sponsor | Indication | Status
Analysts suggest that OKSN-191 emerged from the (Future Control Systems) program, paralleling the U.S. Joint All-Domain Command and Control (JADC2) concept but with heavier emphasis on electronic warfare and cognitive radio. Analysts suggest that OKSN-191 emerged from the (Future